AUTHORS
Bin Zhang, PhD, Jacob Fischman2, Katerina Su3, Adhithi Rajagopalan, MD PhD4, Sophia Chen, MD5, Alexander P. Boardman, MD6, Marcel R.M. van den Brink Jr, M.D., Ph.D.7, Scott E. James, MD,PhD8
AFFILIATIONS
1 City of Hope National Medical Center, Duarte, California, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Antigen-loss escape and progressive T cell exhaustion are major causes of CAR T cell failure. Dual-targeting CAR T cells can reduce antigen relapse, but co-expression of receptors also increases signaling and can accelerate T cell dysfunction. While moderate and transient NFAT activation stimulates productive CAR T cell activation, strong or prolonged NFAT activation promotes exhaustion. We hypothesized that selective modulation of CAR T cell signaling via NFAT attenuation could improve CAR T cell persistence and function without broadly suppressing anti-tumor activity.
We first asked how the degree of NFAT attenuation shapes CAR T cell activity. In our CD19/CD20 dual-CAR system, tonic and repeated antigen stimulation increased expression of NFAT-associated inhibitory receptors PD-1 and LAG-3 and exhaustion-related transcription factor TOX. To attenuate NFAT activity, we engineered dual-CAR T cells with a range of vector-encoded calcineurin-antagonist peptide constructs. We measured NFAT reporter activity, inhibitory receptor expression, proliferation, degranulation, and tumor killing after graded TCR or CAR stimulation. Increasing NFAT attenuation produced a graded reduction in PD-1 and LAG-3, consistent with NFAT dependence of the genes encoding these inhibitory receptors. Moderate NFAT attenuation preserved T cell proliferation, degranulation, and target killing, including against antigen-low target cells. CAR-stimulated AP-1 transcription factor reporter activity was not impaired by NFAT attenuation, consistent with selective NFAT attenuation. These findings defined a window in which NFAT attenuation limited activation of inhibitory programs while maintaining effector activity.
We next tested whether constitutive NFAT attenuation improved CAR T cell function in vivo. We established immunocompetent mice bearing a heterogeneous mixture of syngeneic BM185-CD19 and BM185-CD20 leukemia as an antigen-loss escape model. We treated them with control or NFAT-attenuated dual-CAR T cells. Under high-leukemia burden stress conditions, control dual-CAR T cells failed to sustain anti-leukemia activity. In contrast, dual-CAR T cells with moderate NFAT attenuation eliminated leukemia, produced long-term survival, and persisted at higher levels in peripheral blood. These results identified chronic NFAT activity as an active constraint on dual-CAR T cell persistence/function and showed that NFAT partial attenuation can improve antitumor activity in vivo.
Because NFAT also supports T cell activation and proliferation, chronic attenuation may eventually impair CAR T cells during prolonged antigen exposure. We therefore built an NF-kappaB-responsive incoherent feed-forward loop (IFFL) regulatory circuit that increases NFAT attenuation as CAR signaling intensifies. This NFAT-attenuating circuit reduced NFAT-dependent inhibitory receptor expression while retaining killing against antigen-low targets. In the same syngeneic leukemia model, IFFL-engineered dual-CAR T cells improved tumor control compared with control cells, demonstrating that CAR-regulated NFAT attenuation can also enhance CAR T cell activity in vivo.
Together, these studies show that engineered regulation of NFAT signaling can improve dual-CAR T cell function and persistence. Both constitutive and CAR-regulated NFAT attenuation improved anti-leukemia activity while preserving killing of antigen-low targets. NFAT regulation can support more durable multi-targeted CAR T cell therapies and reduce relapse driven by both antigen escape and progressive T cell dysfunction.
DISCLOSURES
Bin Zhang, PhD: No relevant conflicts of interest to declare.